Globus Medical, Inc. Q2 FY26 Earnings Analysis

- U.S. Spine business expected to continue strong growth, with recent quarters showing around 10% growth, driven mainly by market share gains. - International Spine business targeting a return to consistent low double-digit growth (around 10% constant currency), with mid-teens growth seen recently influenced by currency and prior-year supply chain disruptions. Long term, international growth expected in the low to mid-double-digit range (12%-15%), focusing on deeper market penetration rather than expanding into new countries. - Enabling Technologies business growing, with 21% revenue increase in Q1 2026, but shifting to more flexible offerings (leases/rentals) possibly moderating upfront revenue recognition. - Trauma and neuromonitoring businesses showing strong growth (over 30%). - Overall guidance for 2026 revenue reaffirmed at $3.18B to $3.22B, implying 8.2% to 9.6% growth over 2025. - Long-term goal is sustainable, profitable growth supported by innovation, increased R&D, and operational efficiencies.

- Globus Medical reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth over 2025. - Non-GAAP diluted EPS guidance was raised to $4.70 to $4.80 from $4.40 to $4.50, implying 18.1% to 20.6% growth over 2025. - EPS growth is driven by margin expansion (gross profit margin sustained above 69% in Q1) and operating leverage from sales growth. - Management expects continued gross margin improvements, targeting mid-70% gross margin long term with ongoing supply chain and manufacturing initiatives. - While top-line growth is expected at high single digits long-term, bottom-line (EPS) growth is expected to outpace revenue growth. - R&D spending will increase, especially in Spine and Enabling Technologies, which may modestly offset some margin gains. - No specific 2027 guidance is provided, but strategic focus remains on sustainable, profitable double-digit EPS growth.

- Capital expenditures were $39.6 million in the recent quarter, representing 5.2% of sales. - Capital allocation priorities remain: - Internal investment in innovative product development. - Capital spending on building sets for global sales force. - Investments in facilities, machinery, and equipment to expand manufacturing footprint. - Continued share repurchase program with $390 million remaining authorized as of March 31, 2026. - Ongoing evaluation of complementary M&A focused on investments driving long-term profitable growth. - Increased focus on R&D spending, especially doubled investment in Spine and Enabling Technologies. - Emphasis on supply chain initiatives to improve cost efficiency and support margin expansion.

- No indication of new fundraising through debt or equity in the current quarter. - Company has $799.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026. - Existing share repurchase program of $500 million initiated in Q2 2025; $110 million purchased so far with $390 million remaining. - Capital allocation priorities include internal investment in product development, supporting sales force expansion, manufacturing investments, share repurchases, and evaluating complementary M&A. - No new debt issuance mentioned; paydown of $450 million convertible debt occurred in Q1 2025. - Focus remains on organic growth and strategic uses of capital rather than new debt or equity fundraising at this time.

The transcript does not provide explicit details on the current or expected orderbook or pending orders. However, relevant insights related to demand and sales outlook include: - The company is experiencing strong demand, with U.S. Spine and International Spine businesses growing well. - There is a focus on growing implant procedures driven by robotic system placements and training. - The Enabling Technology segment is shifting towards more rental/leasing models, which creates a larger pipeline but affects upfront revenue recognition. - Management emphasizes smart growth, going deeper into existing markets rather than expanding into new countries. - Despite competitive dynamics elongating deal cycles, Excelsius robotics remains well-positioned with unique technology. - No explicit quantitative order backlog or pending order numbers are disclosed on the call.